Hyperlipoproteinemias:

Indications for PRALUENT:

To reduce the risk of MI, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease. Adjunct to diet, alone or in combination with other lipid-lowering therapies (eg, statins, ezetimibe) in adults with primary hyperlipidemia (including heterozygous familial hypercholesterolemia [HeFH]) to reduce LDL-C.

Adult:

Give by SC inj into thigh, abdomen, or upper arm; rotate inj sites. Initially 75mg once every 2 weeks. Measure LDL-C levels within 4–8 weeks of initiation or titration; may increase to max 150mg given every 2 weeks if LDL-C response is inadequate. Alternative monthly regimen: initially 300mg (two 150mg injs consecutively at two different sites) once every 4 weeks. Measure LDL-C levels just prior to next scheduled dose; may adjust dose to 150mg every 2 weeks, starting on next scheduled dosing date if LDL-C response is inadequate. HeFH undergoing LDL apheresis: 150mg once every 2 weeks; may give without regard to apheresis timing.

Children:

Not established.

Warnings/Precautions:

Do not inject into areas of active skin disease or injury (eg, sunburns, rashes, inflammation, skin infections). Discontinue if serious allergic reactions occur. Pregnancy (2nd & 3rd trimesters). Nursing mothers.

Pharmacologic Class:

Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor.

Interactions:

Avoid co-administration with other injectable drugs at same inj site.

Adverse Reactions:

Nasopharyngitis, inj site reactions (eg, erythema/redness, itching, swelling, pain/tenderness), influenza.

Note:

To enroll pregnant women exposed to Praluent during pregnancy, call (877) 311-8972.

Generic Availability:

NO

How Supplied:

Single-dose prefilled pen or syringe (1mL)—1, 2

Pricing for PRALUENT

2 pens of 75mg/ml carton (Qty: 1)
Appx. price $1118
GoodRx